(Q38149315)

29 August 2017

title

Myelodysplastic syndromes: toward a risk-adapted treatment approach (English)

1 reference

29 August 2017

Bishoy Faltas

1

0 references

author name string

Amer Zeidan

series ordinal

2

1 reference

29 August 2017

Usama Gergis

series ordinal

3

1 reference

29 August 2017

publication date

4 October 2013

1 reference

Expert Review of Hematology

29 August 2017

published in

1 reference

29 August 2017

volume

6

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

611-624

1 reference

Epidemiology of myelodysplastic syndromes

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Myelodysplastic syndromes: the complexity of stem-cell diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Myelodysplastic syndromes--coping with ineffective hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Unraveling the molecular pathophysiology of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Updates in cytogenetics and molecular markers in MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Iron chelation therapy in myelodysplastic syndromes: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Immunomodulatory therapy for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

The 5q- syndrome: biology and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

MDS: Refining existing therapy through improved biologic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

5-Azacytidine/Azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Myelodysplastic syndromes: what do hospitalists need to know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.840997

10.1586/17474086.2013.840997

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference